BMS-955176

Research use only, not for human use.

BMS-955176 (GSK-3532795) is a second-generation HIV-1 maturation inhibitor that exhibits potent activity (EC50=3.9±3.4 nM) against a library (n=87) of gag/pr recombinant viruses.

BMS-955176 (GSK-3532795) is a second-generation HIV-1 maturation inhibitor that exhibits potent activity (EC50=3.9±3.4 nM) against a library (n=87) of gag/pr recombinant viruses; exhibits median EC50 of 21 nM toward a library of subtype B clinical isolates assayed in PBMCs; inhibits HIV-1 protease cleavage at the CA/SP1 junction within Gag in VLPs and in HIV-1-infected cells, and binds reversibly and with high affinity to assembled Gag in purified HIV-1 VLPs; has a greatly improved preclinical profile compared to that of Bevirimat.HIV Infection Phase 2 Clinical.

GSK3532795 exhibits Kds of 3.2 ± 0.6, 4.3 ± 2.0, 6.5 ± 2.2 and 33.6 ± 5.9 nM for HIV WT, HIV V362I, HIV V370A, HIV ΔV370, respectively.

——

GSK-3532795 | BMS955176

Microbiology/Virology

HIV

HIV

Infection

HIV Infection

1392312-45-6

691.03

C42H62N2O4S

>98% (HPLC)

——

CC(=C)C1CCC2(C1C3CCC4C(C3(CC2)C)(CCC5C4(CC=C(C5(C)C)C6=CC=C(C=C6)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7

Benzoic acid, 4-[17-[[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]amino]-28-norlupa-2,20(29)-dien-3-yl]-

(-20℃)

With Ice Pack

≥ 2 years